TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04148261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Acetate (CORT)
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate (CORT)
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PLB)
Description: Participants will receive a placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PLB)
Description: Participants will receive a placebo
Study: NCT01096147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation with eight polar electrode
Description: In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
Study: NCT02736032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum Estradiol and Progesterone levels
Description: Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum Estradiol and Progesterone levels
Description: Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: GnRH agonist given on day 21 of the cycle preceding the embryo transfer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Estradiol
Description: Estradiol started on day1 of the cycle for endometrial prepartaion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Estradiol
Description: Estradiol started on day1 of the cycle for endometrial prepartaion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: progesterone as luteal phase support start after endometrium is well prepared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: progesterone as luteal phase support start after endometrium is well prepared
Study: NCT01263041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
Study: NCT06011720

Intervention type: OTHER
Intervention: Improved transition of care.
Description: Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
Study: NCT04458844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
Study: NCT02069665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Suspension
Description: taken under prescription

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: taken under prescription
Study: NCT01101802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Arm 2 patients were given 2 sugar pills bd for 8 weeks
Study: NCT03664232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
Study: NCT03162900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Therapeutic Exposure
Description: Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Supra-therapeutic Exposure
Description: Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
Study: NCT03664232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a matching placebo orally twice daily for 12 weeks.
Study: NCT03415828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethanol gel
Description: Intradiscal injection of ethanol gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: Intradiscal infiltration of steroids
Study: NCT01902173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT03162900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control (Moxifloxacin)
Description: Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Subjects will receive placebo dose followed by ECG and PK assessments.
Study: NCT01093703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Adjustment
Description: 1. Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~2. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~3. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~4. Awake SBP\>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time.
Study: NCT02885116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow (NHF) supplementation
Description: use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: oxygen supplementation
Description: hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
Study: NCT04477278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: History of Osteopathy
Description: The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
Study: NCT04489069

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical and Neuropsychological evaluations
Description: Clinical interviews and neuropsychological tests (paper/pencil and computer based)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Drawing DNA sample
Description: Saliva sample
Study: NCT03728205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly yoga sessions for 12 weeks
Study: NCT04172558

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimix
Description: on demand ICI of Trimix
Study: NCT00681239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet and KetoCal
Description: 10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
Study: NCT02239822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the trigeminal nerve (active stimulation)
Description: Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation of the trigeminal nerve (placebo)
Description: Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
Study: NCT04110041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
Study: NCT01154933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide 5 mcg
Description: exenatide 5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide 10 mcg
Description: exenatide 10 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline sq
Study: NCT02978482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab + durvalumab
Description: 20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
Study: NCT01037673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Movement exercises
Description: A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
Study: NCT01409460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oburator Nerve block
Description: Use of selective pain block.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection in pectineus muscle.
Description: Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
Study: NCT03454854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent terminal APP
Description: Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
Study: NCT02899858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Assessment
Description: Documentation of ASIA A (T2-8) status at Belmont Gait Lab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Total MRI of spine to evaluate condition of spinal cord

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IntraSpinal Micro-Stimulation
Description: IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up clinical exam
Description: All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Op MRI Scan
Description: An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up gait assessment
Description: Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
Study: NCT04513470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
Study: NCT00481845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg daily
Study: NCT04285333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia iliaca block
Description: ultrasound guided block with 20 mL lidocaine 1.5%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percapsular nerve group block
Description: ultrasound guided block with 20 mL lidocaine 1.5%
Study: NCT02594436

Intervention type: DRUG
Intervention: Ingenol mebutate
Description: Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling

Intervention type: DRUG
Intervention: Ingenol mebutate
Description: Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
Study: NCT00004029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant viral vaccine therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT00880256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction
Description: An 8-week course in mindfulness training
Study: NCT02640963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
Study: NCT00457496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive, behavioral, exercise
Description: Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
Study: NCT01303055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily : two years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 750 mg
Description: Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %.
Study: NCT01618760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Tablet 1 mg
Description: 1 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg tablet once a day
Study: NCT00697957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive impact exercise
Study: NCT01234155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training - Interval Walking
Description: Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise - Continuous Walking
Description: Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
Study: NCT00617877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Study: NCT01726179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.